CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Cytosorbents Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$4.96+0.85 (+20.68%)

Close on Oct 19, 2026

Market cap: $311.52M
P/E (TTM): –
Dividend yield: –

Cytosorbents Corp cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Depreciation & Amortization	1.23	1.34	1.46	0.88	0.73	0.66	0.58	0.39	0.22	0.16	0.11	0.07	0.06	0.05	0.04	0.02
Stock-Based Compensation	2.77	3.76	4.16	3.42	4.02	3.51	1.67	4.44	3.31	2.76	0.38	0.70	0.46	0.06	0.87	–
Change in Accounts Receivable	0.42	-1.72	-0.25	-1.29	0.42	-0.33	-0.64	-1.85	-0.65	-0.89	0.13	-0.41	-0.40	-0.02	-0.04	–
Change in Inventory	-2.54	0.50	0.18	0.95	-2.35	-0.46	-1.28	-0.06	0.06	0.34	-0.67	-0.31	0.44	-0.25	-0.43	–
Change in Accounts Payable	-0.71	-1.81	1.61	-3.25	2.43	1.11	1.42	1.70	-0.17	1.63	-0.08	0.50	0.12	0.15	-0.03	0.19
Change in Unearned Revenue	–	–	–	–	–	–	–	–	0	0	0.00	-0.27	0.27	–	–	–
Operating Cash Flow	-12	-14	-22	-28	-14	-5.61	-17	-11	-6.46	-6.73	-9.05	-6.28	-3.49	-3.62	-3.83	-2.48
Capital Expenditures	-0.16	-0.28	-0.54	-6.09	-3.64	-0.71	-0.70	-0.67	-0.99	-0.14	-0.40	-0.15	-0.04	-0.02	-0.03	-0.14
Sale of Property, Plant & Equipment	0.08	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Purchase of Investments	–	–	–	–	–	–	–	–	0	0	-5.68	-6.69	–	–	–	–
Sale & Maturity of Investments	–	–	–	–	–	–	–	0	0	2.19	5.43	4.75	–	–	–	–
Investing Cash Flow	-0.42	-0.67	-0.94	-6.46	-4.28	-1.68	-1.52	-1.52	-1.68	1.60	-0.89	-2.31	-0.22	-0.04	-0.05	-0.17
Stock Issued	–	–	–	–	27	27	14	10	10	–	–	–	–	–	–	–
Debt Issued	2.48	15	–	5.00	–	1.41	5.00	0.67	5.00	5.00	0	0	–	–	–	–
Debt Repaid	–	-5.00	–	–	–	-16	0	-0.67	0	0	–	–	–	–	–	–
Financing Cash Flow	9.31	9.33	14	4.96	0.72	66	8.18	17	20	5.06	12	10	4.20	4.21	4.01	2.10
Foreign Exchange Rate Adjustments	1.49	-0.09	-0.10	-0.26	-0.02	0.13	-0.04	-0.06	0.09	0.00	0.01	0.00	-0.04	-0.01	–	–
Net Change in Cash	-1.99	-5.85	-8.22	-30	-18	59	-10	5.05	12	-0.07	1.71	1.42	0.45	0.54	0.13	-0.54
Free Cash Flow	-13	-15	-22	-34	-18	-6.32	-17	-12	-7.45	-6.87	-9.45	-6.43	-3.53	-3.64	-3.86	-2.62
Income Taxes Paid	-1.71	-0.88	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest Paid	2.08	1.29	0.38	–	–	1.13	1.06	0.89	0.63	0.18	0	0	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 71.6%
Operating margin: -34.7%
Net margin: -48.9%
Return on equity, FY2025: -96.4%

Financial strength

Current ratio: 0.66
Debt to equity: -22.96
Debt to assets: 45.4%
Cash to current liabilities: 18.4%

Valuation

P/E ratio: –
Price to sales: 8.37
Price to book: –
Dividend yield: –